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Introduction
Cisplatin is a major chemotherapy drug for the treatment 
of solid tumors. It leads to accumulation of platinum within 
the kidney and disturb renal tubular tissue and function. 
However its side effects in normal tissues and organs, 
notably nephrotoxicity in the kidneys, cause dose limiting 
in therapeutics. Side effects in normal tissues, including 
neurotoxicity, ototoxicity, nausea and vomiting are 
liming factors of cisplatin use (1). Mechanism of cisplatin 
nephrotoxicity in the kidney revealed: 1) a decrease in 
renal blood flow and glomerular filtration rate, 2) tubular 
necrosis/apoptosis, 3) increased lipid peroxidation 
and decreased endogenous antioxidant systems, 4) 
increased expression of inflammation markers and 5) 
increased activity of the apoptosis executioner caspase-3. 
Renoprotective approaches are being discovered, but the 
protective effects are mostly unknown, recommending 
the need for combinatorial strategies whilst it is unclear 
whether these approaches would limit the anticancer 
effects of cisplatin in tumors (2). 
Renoprotective strategies against cisplatin therapy
These approaches can be generally classified on 8 targets: 
1)  Decrease of cisplatin uptake by renal cells,  2) Inhibition 
of cisplatin metabolism,  3) Blocking cell death pathways, 
4) Cyclin-dependent kinase inhibitors, 5) Pharmacologic, 
molecular, and genetic blockade of p53, 6) Inhibition of 
specific Mitogen-activated protein kinases (MAPKs), 7) 
Antioxidants usage for renoprotection against cisplatin 
injury and inhibit of oxidative stress, 8) Suppress of 
inflammation (3-6).
Cisplatin is used for the treatment of testicular, head and 
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Nephrotoxicity is the major limitation for the clinical use of cisplatin as an anti-tumoural 
drug. Intracellular effects of cisplatin cause tubular damage and tubular dysfunction with 
sodium, potassium, and magnesium wasting. Renoperotective strategies against cisplatin are 
classified on 8 targets: 1)  Decrease of cisplatin uptake by renal cell,  2) Inhibition of cisplatin 
metabolism,  3) Blocking cell death pathways, 4) Cyclin-dependent kinase inhibitors, 5) 
Pharmacologic, molecular, and genetic blockade of p53, 6) Inhibition of specific Mitogen-
activated protein kinase, 7) Antioxidants usage for renoprotection against cisplatin injury 
and inhibit of oxidative stress, 8) Suppress of inflammation. The oxidation reactions can 
produce free radicals, which start chain reactions and subsequently can cause a large number 
of diseases in humans. Antioxidant from natural products have attracted the physicians’ 
attentions, nowadays. The natural product antioxidants detoxify reactive oxygen species 
(ROS) in kidneys, without affecting the anticancer efficacy of cisplatin. Hence, antioxidants 
have potential therapeutic applications.
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neck, ovarian, cervical, nonsmall cell lung carcinoma, and 
many other types of cancer. The molecular mechanism of 
anticancer of cisplatin is bound to DNA, leading to the 
formation of inter- and intra-strand cross-links which 
activate several signal transduction pathways, involving 
p53, p73, and MAPK, and reach the highest activation of 
apoptosis. DNA damage-mediated apoptotic signals, can 
be attenuated, and the resistance that occurs is a major 
limitation of cisplatin-based therapeutics (7-10).
Cisplatin nephrotoxicity
Nephrotoxicity of cisplatin is often seen after 10 days and 
complications include lower glomerular filtration rate, 
higher serum creatinine, and reduced serum magnesium 
or potassium levels. Cisplatin-induced kidney injury is 
associated with increased kidney vascular resistance and 
histological damage to proximal tubular cells resulting in 
decreased blood flow and ischemic injury of the kidneys, 
contributing to a decline in glomerular filtration rate. The 
cytotoxicity of cisplatin has multiple intracellular effects, 
including regulating genes, causing direct cytotoxicity 
with reactive oxygen species (ROS), activating MAPKs, 
apoptosis, stimulating inflammation and fibrogenesis. 
These events cause tubular damage and tubular 
dysfunction with sodium, potassium, and magnesium 
wasting. It is due to a combination of cell membrane 
peroxidation, mitochondrial dysfunction, inhibition of 
protein synthesis, and DNA injury. These events conclude 
the loss of renal function during cisplatin nephrotoxicity, 
and acute renal failure (11,12).
The cellular pathway of cisplatin injury of kidney cells  
Cisplatin increases ROS production via the disrupted 
respiratory chain and induce mitochondrial dysfunction. 
Cisplatin induces ROS formation in the microsomes via 
the cytochrome P450 system. This drug causes break 
down of nuclear and mitochondrial DNA and production 
of ROS leads to activation of both mitochondrial and non-
mitochondrial pathways of apoptosis and necrosis. ROS 
in renal epithelial cells reduce the activity of antioxidant 
enzymes and deplete intracellular concentrations of 
glutathione (GSH). Nephrotoxicity of cisplatin is amassing 
of it in the tubular epithelial cells of proximal kidney 
tubule and is characterized by morphological destruction 
of intracellular organelles and cellular necrosis (13,14). 
Oxidative stress plays an important role in development of 
kidney disease including glomerular injury or promoting 
hypertension and atherosclerosis or kidney ischemia. 
In addition, it consequences decrease of natural cell 
antioxidant capacity or increase in quantity of ROS in 
kidney. Numerous studies have reported toxic effects of 
cisplatin induced nephrotoxicity. A growing amount of 
results provide evidence that toxic drugs are capable of 
interacting with nuclear proteins and deoxyribonucleic 
acid (DNA) causing oxidative deterioration of biological 
macromolecules (15,16).
Recent studies have focused on the role of antioxidants 
in cisplatin toxicity. Also the oxidative stress induced 
cisplatin in the kidney was partially inhibited by 
antioxidant therapy using antioxidants such as vitamin C 
or E, flavonoids, superoxide dismutase, glutathione and 
selenium, as well as plants antioxidants (17).
The antioxidants are bioactive molecules which are 
capable of decreasing or preventing the oxidation of 
substrate molecules. The oxidation reactions can produce 
free radicals, which start chain reactions and subsequently 
can cause a large number of diseases in humans (18). 
Antioxidant from natural products have attracted a lot of 
attentions, nowadays. The natural product antioxidants 
may detoxify ROS in kidneys, without affecting the 
anticancer efficacy of cisplatin. Hence, antioxidants have 
potential therapeutic applications. 
Antioxidant compounds remove free radical 
intermediates, and inhibit other oxidation reactions by 
being oxidized themselves (18-22). Antioxidants trap free 
radicals, terminating the chain reaction by chelating metal 
ion and preventing the reaction with ROS or by chelating 
metal and protecting against metal toxicity (23). Chelating 
metal are capable of binding to toxic metal ions to form 
complex structures which are easily excreted from the 
body removing them from intracellular or extracellular 
spaces. The concept of cisplatin therapeutic is based on 
simple coordination of herbal plants, evolution of an ideal 
chelator and chelation therapy that completely removes 
specific toxic metal from desired site in the body which 
involves an integrated drug design approach (24-26).
Some herbal medicines have also been shown to protect 
kidney injury. Natural products from medical plants have 
capacity to ameliorate oxidative stress. Phytochemicals 
play an important role as natural antioxidants and 
immunomodulators (27-31). 
Natural antioxidants
Antioxidant compounds including tocopherols, 
flavonoids, carotenoids, and phenolic compounds 
can inhibit Fe3+ induced oxidation and scavenge free 
radicals. Also they act as reductants spices and are used 
in medicine. It is notable that phenolic compounds 
have strong H-donating activity. Antioxidants protect 
biomolecules from free radical damage induced by both 
ROS and reactive nitrogen species (RNS) (32,33).
The plant phenolic antioxidants are divided into four 
general groups: phenolic diterpenes (carnosol and 
carnosic acid), phenolic acids (gallic, protocatechuic, 
caffeic, and rosmarinic acids), flavonoids (quercetin and 
catechin), and volatile oils (menthol). Generally phenolic 
acids act as antioxidants by trapping free radicals and 
flavonoids can scavenge free radicals and chelate metals as 
well and biological aspects of antioxidants are particularly 
related to their chelating properties.
Also flavonoids with multiple hydroxyl groups are more 
effective antioxidants than the other ones with only 
one (34-36).
In agreement with prior investigations, we found that 
cisplatin induced tubular injury, increased inflammatory 
cell infiltration, oxidative/nitrative stress and impaired 
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renal function. Cisplatin-induced tubular damage and 
nephropathy revealed by mitochondria injury and oxidant 
stress (37).
We recently conducted another investigation on rat 
model of cisplatin nephrotoxicity and observed that in 
addition to antioxidants, losartan may prevent cisplatin 
nephrotoxicity in males. We also recently observed that, 
vitamin E and vitamin C are chemoprotective agents 
against cisplatin nephrotoxicity. Also Selenium is a 
component of the antioxidant for enzymes glutathione 
peroxidase and thioredoxin reductase (38,39). Notably, 
magnesium supplementation during chemotherapy with 
cisplatin/paclitaxel is a nephroprotective management 
with no reduction of antitumor efficacy (40). We noticed 
that, erythropoietin is capable of protecting renal injury, 
and may lead to different responses against cisplatin-
kidney injury in rat model. We found that, treatment by 
recombinant human erythropoietin (Eprex) abolished 
changes in blood urea nitrogen and creatinine levels in 
rat model (41,42). Also oxytocin ameliorates cisplatin-
induced nephrotoxicity (43).
Investigations have revealed that crude caffeine did 
possess hydrophilic antioxidant activity and lipophilic 
antioxidant activity, and its administration has led to the 
inhibition of cyclooxygenase-2 enzyme. Also, caffeine is 
able to recover toxicity of cisplatin (44,45).
We also observed that cisplatin lonely increased 
kidney damage significantly, but the injury induced by 
combination of cisplatin and nitric oxide synthase can 
inhibit the damage of the kidney (46). 
Antioxidants are different substances such as vitamin C, 
vitamin E, carotenoids, minerals such as selenium and 
manganese, as well as glutathione, coenzyme Q10, lipoic 
acid, phytoestrogens, flavonoids, phenols, and polyphenols 
which largely prevent the functional and structural lesions 
in tubular of kidney. These agents can prevent cisplatin 
induce mitochondrial production of oxidants which are 
the key to its ability to injure mitochondria (37-47).
In case of cisplatin toxicity, due to excess production of 
highly reactive free radicals, an imbalance occurs in the 
oxidant-antioxidant status leading to depletion in the 
activities of antioxidants as well as an elevation in lipid 
peroxidation. ROS like hydrogen peroxide, superoxide 
and hydroxyl radicals generated under normal metabolic 
conditions are generally detoxified by the activities 
of antioxidants like reduced glutathione, superoxide 
dismutase (SOD) and catalase (CAT). The activities of 
key enzymatic antioxidants like SOD, CAT, glutathione 
peroxidase (GPx) and glutathione S-transferase (GST) were 
found decreased in cisplatin induced nephrotoxic (48).
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